Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level Bio ABFRA:4MB -31.25%23 14-Day RSI is 51.15 as of Jul. 21, 2026. GuruFocus rates FRA:4MB with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Level Bio AB ranks better than 57.14% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-21), Level Bio AB's 14-Day RSI is 51.15.
The industry rank for Level Bio AB's 14-Day RSI or its related term are showing as below:
FRA:4MB's 14-Day RSI is ranked better than 57.14% of 217
companies
in the Medical Diagnostics & Research industry
Industry Median: 48.08
vs FRA:4MB: 51.15
Level Bio AB (FRA:4MB) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Level Bio AB 14-Day RSI Related Terms
FRA:4MB vs TMO, DHR, IDXX: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, Level Bio AB's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Bio AB 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Level Bio AB's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Level Bio AB's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Bio AB (FRA:4MB) has a 14-Day RSI of 51.15 as of Jul. 21, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Level Bio AB and its competitors. According to the industry distribution chart, Level Bio AB ranks #93 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 42.9%.
Is Level Bio AB's 14-Day RSI too high?
Level Bio AB's current 14-Day RSI is 51.15. The Medical Diagnostics & Research industry median 14-Day RSI is 48.08. Level Bio AB's value of 51.15 is 6.4% above this industry median. Based on the distribution chart, Level Bio AB ranks #93 out of 217 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Level Bio AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Level Bio AB's 14-Day RSI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Level Bio AB ranks #93 out of 217 companies for 14-Day RSI. This puts Level Bio AB in the upper half of its industry. The industry median 14-Day RSI is 48.08. Level Bio AB's value of 51.15 is 6.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 48.08, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Level Bio AB's current 14-Day RSI of 51.15 is 6.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Level Bio AB and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 48.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Bio AB's current 14-Day RSI is 51.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Bio AB stock overvalued right now?
Level Bio AB (FRA:4MB) has a current 14-Day RSI of 51.15. The current 14-Day RSI is 51.15 and 6.4% above the Medical Diagnostics & Research industry median of 48.08. Level Bio AB's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Level Bio AB (FRA:4MB), the current 14-Day RSI is 51.15 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.
23GF Score
Get the complete analysis for FRA:4MB
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4MB has been successfully added to your 
